Retinora

Retinora is the free app for patients with wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It helps you manage your daily life with a retinal disease more easily.

This intuitive app was developed in collaboration with patients to provide optimal support at every stage of your treatment and make your life easier.

HOW RETINORA SUPPORTS YOU:

1. Keep track of your health:

Track your well-being and lifestyle daily – easily and intuitively with smileys and automatically via Google Health Connect. This helps you quickly see how your macular degeneration affects your daily life.

2. Analyze progress and recognize patterns:

Compare your progress over weeks, months, or years in clear graphs. Identify correlations and gain valuable insights into long-term health trends to better understand the progression of your retinal disease.

3. Set goals & stay motivated:

Define personal health goals and track your progress. Stay motivated by clear successes.

4. Prepare optimally for doctor's appointments:

Don't just plan your next appointments, but prepare for them step by step: Select the appointment type and receive suggestions for important questions to ask your healthcare team. A personal checklist will help you prepare.

5. Record medications & get reminders:

Record current and past medications, enter flexible dosages, and activate reminders. This way, you won't miss any doses and you'll keep track of your medication.

6. Learn about your diagnosis:

Discover current, easy-to-understand, and practical information about your condition—whether it's wet AMD, DME, or RVO.

---

We are developing Retinora together with you—for an app that sustainably simplifies your daily life with your eye condition.

Important note: Retinora does not replace a medical diagnosis or treatment recommendation. Please always consult your healthcare team with medical questions.

... The Retinora app is developed by Temedica GmbH in cooperation with Roche Pharma AG. Retinora is aimed at people diagnosed with nAMD, DME, or RVV.